Makary makes many claims here that sound like "common sense" but are problematic. 1st he says FDA's reg reqs have made the US "less competitive in the global race for new drugs and treatments." I'm not aware of any sponsor planning to skip the US market. www.washingtonpost.com/opinions/202...